Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination

Nano Dimension (NNDM) and Infinite Epigenetics have jointly released clarifying statements regarding their proposed business combination, addressing investor concerns raised by Murchinson Ltd. This announcement represents a routine corporate communication aimed at providing transparency on deal rationale and operational fundamentals rather than a material market catalyst.

The companies emphasized Infinite's business model architecture, market addressable opportunity, and capital deployment strategy. Such disclosure typically follows shareholder opposition or activist scrutiny, signaling management's effort to rebuild confidence in merger economics. The detailed explanations suggest potential valuation concerns or execution questions among stakeholders.

For NNDM shareholders, this communication reflects deal integration complexity and the need for ongoing stakeholder reassurance. The provision of additional color on business fundamentals and capital plans indicates management confidence but also acknowledges prior communication gaps. This type of iterative disclosure often precedes voting events or regulatory approvals.

Sector implication: Technology-focused special purpose acquisition and merger activity remains subject to heightened scrutiny post-2023 market reset. This disclosure pattern is consistent with deals undergoing extended integration timelines and increased due diligence expectations, particularly in biotech-adjacent technology spaces.